Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,020 public trials 2,031 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial

NCT05066555

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico Avellino, Italy
  • IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia Bari, Italy
  • ASST Spedali Civili di Brescia - Ematologia Brescia, Italy
  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia Milan, Italy
View all 13 locations
View Trial Details
Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

NCT03787264

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Universitätsklinik Köln Cologne, Germany
  • Gemeinschaftspraxis Hämatologie Onkologie Dresden, Germany
  • Gemeinschaftspraxis Mohm/Prange-Krex Dresden, Germany
  • Universitatsklinik Carl Gustav Carus Dresden, Germany
View all 17 locations
View Trial Details
Completed

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

NCT02950051

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Medizinische Universitaet Wien Vienna, Austria
  • Hanusch Hospital Vienna, Austria
  • Wilhelminenspital Vienna, Austria
  • ZNA Stuivenberg Antwerp, Belgium
View all 161 locations
View Trial Details
Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT03484702

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Local Institution - 101 Vienna, Austria
  • Local Institution - 351 Ghent, Belgium
  • Local Institution - 551 Helsinki, Finland
  • Local Institution - 202 Lille, France
View all 20 locations
View Trial Details
Completed

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

NCT03189524

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
  • Jiangsu Province Hospital Nanjing, Jiangsu, China
  • Institute of Hematology and Hospital of Blood Disease Tianjin, Tianjin Municipality, China
View Trial Details
Completed

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968

Conditions
Adnexal Diseases, Blood Protein Disorders, Breast Cancer, +68 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Stanford Comprehensive Cancer Center Stanford, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists and Research Institute Sarasota, Florida, United States
View all 16 locations
View Trial Details
Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details

Related conditions